In TNBC, combining BET inhibitor with paclitaxel and PD-L1 blockade further remodels the tumor microenvironment, promoting immunogenic and senescent transcriptional programs that enhance therapeutic efficacy (186). This evidence concerns the gene CD274 and neoplasm.